Abstract
Multiple sclerosis (MS) is a central nervous system demyelinating disease of implicated autoimmune aetiology. The effect was evaluated of intravenous gammaglobulin (IVIg), a successful therapy in various autoimmune diseases, in relapsing-remitting MS patients treated for three years. IVIg treatment significantly reduced the number and severity of acute exacerbations and resulted in a lesser neurological disability. There were no significant short or long-term adverse effects to IVIg treatment. To clarify the putative therapeutic effects of IVIg, this treatment was examined in the animal model of experimental autoimmune encephalomyelitis (EAE) in the rat. IVIg suppressed active EAE in relation to disease severity and duration, despite the presence of T-cell reactivity to specific antigens, while the treatment had no effect on passive EAE induced by adoptive transfer of myelin basic protein specific CD4 + T-cells. It is concluded that IVIg treatment may be a promising treatment in relapsing-remitting MS as it can alter the natural course of the disease.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Achiron A., Pras E., Gilad R., Ziv I., Mandel M., Gordon C. R., Noy S., Sarova-Pinhas I., Melamed E. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992 Dec;49(12):1233–1236. doi: 10.1001/archneur.1992.00530360031013. [DOI] [PubMed] [Google Scholar]
- Golaz J., Steck A., Moretta L. Activated T lymphocytes in patients with multiple sclerosis. Neurology. 1983 Oct;33(10):1371–1373. doi: 10.1212/wnl.33.10.1371. [DOI] [PubMed] [Google Scholar]
- Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
- Lemire J. M., Weigle W. O. Myelin basic protein-specific T cell clones and experimental allergic encephalomyelitis. Pathol Immunopathol Res. 1986;5(3-5):248–252. doi: 10.1159/000157018. [DOI] [PubMed] [Google Scholar]
- Mokhtarian F., McFarlin D. E., Raine C. S. Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice. Nature. 1984 May 24;309(5966):356–358. doi: 10.1038/309356a0. [DOI] [PubMed] [Google Scholar]
- Mor F., Cohen I. R. T cells in the lesion of experimental autoimmune encephalomyelitis. Enrichment for reactivities to myelin basic protein and to heat shock proteins. J Clin Invest. 1992 Dec;90(6):2447–2455. doi: 10.1172/JCI116136. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Noronha A., Toscas A., Jensen M. A. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol. 1990 Feb;27(2):207–210. doi: 10.1002/ana.410270219. [DOI] [PubMed] [Google Scholar]
- Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
- Waksman B. H., Reynolds W. E. Multiple sclerosis as a disease of immune regulation. Proc Soc Exp Biol Med. 1984 Mar;175(3):282–294. doi: 10.3181/00379727-175-41798. [DOI] [PubMed] [Google Scholar]
- Zamvil S. S., Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol. 1990;8:579–621. doi: 10.1146/annurev.iy.08.040190.003051. [DOI] [PubMed] [Google Scholar]